Skip to main content

20 publications

Name Date Type Actions

Third quarter revenues: €132 million

14/10/2021 Public releases

2021 first half results

2021 Half year results

29/07/2021 Public releases

Availability of the 2020 universal registration document

Vetoquinol informs that it has filed its 2020 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 28th, 2021.

28/04/2021 Public releases

Q1 2021 sales

Q1 2021 sales : €128M (up 28% at constant exchange rates, up 24% as reported)
Q1 2021 essential sales : €72.6M (up 38% at constant exchange rates, up 36% as reported)

15/04/2021 Public releases

2020 annual results 2020 sales: €427.5m (up 8.0% as reported)

EBIT before depreciation of assets arising from acquisitions: €65.3m (up 33.5%)
Net income - Group share: €19.2m (4.5% of sales)
Cash flow: €92.2m

01/04/2021 Public releases

Vetoquinol wins the Animal Pharm’s award for best European company 2020

February 8th, 2021 (Lure, France) - Vetoquinol announced today it has been awarded “Best European Company 2020” by Animal Pharm.

08/02/2021 Public releases

Vetoquinol acquires the rights for Profender® from Elanco Animal Health for Canada

February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health.

08/02/2021 press release excluding results

2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate)

Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.

21/01/2021 Public releases

Orion Animal Health and Vetoquinol expand collaboration - Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania

Orion Animal Health and Vetoquinol are expanding their collaboration with new distribution agreements.

18/01/2021 Public releases

Vetoquinol acquires the rights for Drontal® and Profender® families from Elanco animal health for Australia

January 11th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Australian rights to Drontal® and Profender® product families from Elanco Animal Health.

11/01/2021 Public releases

Forcyl® - a booming brand

Lure (France), November 14, 2012 – Vétoquinol receives a new indication for its Forcyl® product, designed for cattle, and a new market authorization for Forcyl® Swine for pigs.

14/11/2012 Public releases

Sales momentum continues in Q3

Vétoquinol posted sales of €220.9 million for the first 9 months of 2012, up 6.2% compared to the same period last year.

25/10/2012 Public releases

Vétoquinol purchases ORSCO laboratoire vétérinaire

Lure (France), September 25, 2012 – Vétoquinol announces the purchase of the entire equity of Orsco Laboratoire Vétérinaire.

25/09/2012 Public releases

Vétoquinol returns to growth

Lure (France), 29 August 2012 – At its 29 August 2012 meeting, the Vétoquinol S.A. board of directors reviewed the Group results and approved the financial statements for the first six months of 2012.

29/08/2012 Public releases

Solid first half 2012 Sales

First half 2012 sales reached €146.8 million, up 5.1% over first half 2011.

17/07/2012 Public releases

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2011 (french version)

The registration document of Vétoquinol relative to fiscal year 2011, including the annual financial report relative to fiscal year 2011, was registered with the Autorité des marchés financiers (“the AMF”) on April 20th, 2012.

23/04/2012 Public releases

Strong Revenue growth in the first quarter of 2012

Vétoquinol achieved Q1 2012 sales of €77.0 million, up 15.9% compared to Q1 2011.

20/04/2012 Public releases

2011 annual earnings

Lure (France), April 03, 2012 – The Vétoquinol Board Meeting of March 26, 2012 has reviewed the Group’s business and approved the 2011 financial statements.

03/04/2012 Public releases

Flevox® the new parasiticide for dogs and cats

Lure (France), 14 February 2012 – Vétoquinol launches Flevox®, the latest addition to its range of parasiticides. The new drug is based on fipronil, the molecule par excellence in the treatment of tick and flea infestations in pets.

14/02/2012 Public releases

2011, a year of transition

Lure (France), January 24, 2012 – In 2011, Vétoquinol achieved sales of €284.1 million, 0.7% up on the previous year and stable on a like-for-like basis.

24/01/2012 Public releases